Literature DB >> 20373907

Evaluation of the Target Inhalation Mode (TIM) breathing maneuver in simulated nebulizer therapy in patients with cystic fibrosis.

John Denyer1, Ivan Prince, Emma Dixon, Penny Agent, Jennifer Pryor, Margaret Hodson.   

Abstract

BACKGROUND: Adaptive Aerosol Delivery (AAD) systems provide efficient drug delivery and improved lung deposition over conventional nebulizers by combining real-time analyses of patient breathing patterns and precisely timed aerosol delivery. Delivery and deposition are further enhanced by breathing techniques involving slow, deep inhalations.
METHODS: This exploratory study assessed the acceptability of slow, deep inhalations in 20 patients with cystic fibrosis (CF) during up to eight simulated nebulizer treatments with the I-neb AAD System. The breathing maneuver, Target Inhalation Mode (TIM) breathing, involved the lengthening of the patient's inhalation time over successive breaths with guidance from auditory and tactile (vibratory) feedback from the device.
RESULTS: At the end of the first treatment, most patients felt that the instructions were easy to understand (90%) and that the vibratory feedback was pleasant (65%). Half of the patients found the procedure to be comfortable. At the end of the final treatment, most patients felt that the breathing maneuver was easy to understand (90%) and use (80%), but that the duration of the breath was too long (100%). Logged data revealed that 90% of patients were able to comply with the breathing maneuver. The two patients unable to comply had a forced vital capacity of <1.75 L. The average treatment time decreased from 288.4 to 141.6 sec during the first and final treatments, respectively.
CONCLUSIONS: This study provides preliminary evidence of the acceptability of the TIM breathing maneuver in patients with CF and their ability to perform repeated TIM breathing during simulated nebulizer therapy with the I-neb AAD System.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20373907      PMCID: PMC3116626          DOI: 10.1089/jamp.2009.0768

Source DB:  PubMed          Journal:  J Aerosol Med Pulm Drug Deliv        ISSN: 1941-2711            Impact factor:   2.849


  21 in total

1.  Inhalation of tobramycin in cystic fibrosis. Part 1: the choice of a nebulizer.

Authors:  P P Le Brun; A H de Boer; D Gjaltema; P Hagedoorn; H G Heijerman; H W Frijlink
Journal:  Int J Pharm       Date:  1999-11-05       Impact factor: 5.875

Review 2.  Pharmaceutical and biotechnological aerosols for cystic fibrosis therapy.

Authors:  Lucila Garcia-Contreras; Anthony J Hickey
Journal:  Adv Drug Deliv Rev       Date:  2002-12-05       Impact factor: 15.470

3.  Comparison of lung deposition of colomycin using the HaloLite and the Pari LC Plus nebulisers in patients with cystic fibrosis.

Authors:  N M Byrne; P M Keavey; J D Perry; F K Gould; D A Spencer
Journal:  Arch Dis Child       Date:  2003-08       Impact factor: 3.791

4.  The daily grind and how to stay sane as a mother of two children with cystic fibrosis.

Authors:  Vanessa Hunter
Journal:  J R Soc Med       Date:  2003       Impact factor: 5.344

Review 5.  Aerosolised antibiotics: a critical appraisal of their use.

Authors:  Jennifer K Hagerman; Kim E Hancock; Michael E Klepser
Journal:  Expert Opin Drug Deliv       Date:  2006-01       Impact factor: 6.648

6.  ATS statement--Snowbird workshop on standardization of spirometry.

Authors: 
Journal:  Am Rev Respir Dis       Date:  1979-05

7.  Administration of aerosolized antibiotics in cystic fibrosis patients.

Authors:  R B Moss
Journal:  Chest       Date:  2001-09       Impact factor: 9.410

Review 8.  Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society.

Authors:  P H Quanjer; G J Tammeling; J E Cotes; O F Pedersen; R Peslin; J C Yernault
Journal:  Eur Respir J Suppl       Date:  1993-03

Review 9.  Nebulised anti-pseudomonal antibiotics for cystic fibrosis.

Authors:  G Ryan; S Mukhopadhyay; M Singh
Journal:  Cochrane Database Syst Rev       Date:  2003

10.  A widely available method for the assessment of aerosol delivery in cystic fibrosis.

Authors:  Jack A Kastelik; Graham A Wright; Imran Aziz; Mal Davies; Gerard R Avery; Alex J Paddon; Sydney Howey; Alyn H Morice
Journal:  Pulm Pharmacol Ther       Date:  2002       Impact factor: 3.410

View more
  6 in total

1.  Intelligent nebulizers in the age of the Internet: The I-neb Adaptive Aerosol Delivery (AAD) system.

Authors:  Rajiv Dhand
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2010-04       Impact factor: 2.849

Review 2.  A path to successful patient outcomes through aerosol drug delivery to children: a narrative review.

Authors:  Arzu Ari
Journal:  Ann Transl Med       Date:  2021-04

Review 3.  The Adaptive Aerosol Delivery (AAD) technology: Past, present, and future.

Authors:  John Denyer; Tony Dyche
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2010-04       Impact factor: 2.849

4.  Mode of breathing-tidal or slow and deep-through the I-neb Adaptive Aerosol Delivery (AAD) system affects lung deposition of (99m)Tc-DTPA.

Authors:  Kurt Nikander; Ivan Prince; Steven Coughlin; Simon Warren; Glyn Taylor
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2010-04       Impact factor: 2.849

5.  Domiciliary experience of the Target Inhalation Mode (TIM) breathing maneuver in patients with cystic fibrosis.

Authors:  John Denyer; Alex Black; Kurt Nikander; Tony Dyche; Ivan Prince
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2010-04       Impact factor: 2.849

Review 6.  Inhaled therapy in cystic fibrosis: agents, devices and regimens.

Authors:  Penny Agent; Helen Parrott
Journal:  Breathe (Sheff)       Date:  2015-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.